* Sanofi press release [https://seekingalpha.com/pr/20278629-press-release-q3-continued-sales-and-earnings-progress] (NASDAQ:SNY [https://seekingalpha.com/symbol/SNY]): Q3 Non-GAAP EPS of €2.30
* GAAP EPS of €2.91
* Revenue of €12.43B (+2.3% Y/Y).
* Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and Ayvakit
* Dupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarter
* Vaccines sales decreased by 7.8% to €3.4 billion, from lower influenza sales
* Research and Development expenses were €1.8 billion, an increase of 4.9%
* Selling, general and administrative expenses were €2.3 billion, up 7.1% to support launches
* Business EPS was €2.91, up 13.2% at CER and 7.0% at actual exchange rates, delivering profitable growth; IFRS EPS was €2.30
MORE ON SANOFI
* Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript [https://seekingalpha.com/article/4825074-sanofi-san-ca-presents-at-bank-of-america-global-healthcare-conference-2025-transcript]
* Historical earnings data for Sanofi [https://seekingalpha.com/symbol/SAN:CA/earnings]
* Financial information for Sanofi [https://seekingalpha.com/symbol/SAN:CA/income-statement]
Sanofi reports Q3 results
Published 2 weeks ago
Oct 24, 2025 at 5:36 AM
Positive
Auto